• The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
  • Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. (ucy.ac.cy)
  • TCHP: Taxotere (also known as docetaxel) carboplatin combined with Herceptin (also known as trastuzumab) and Perjeta (also known as pertuzumab). (uwhealth.org)
  • 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. (kjco.org)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • For platinum-resistant or platinum-sensitive ovarian cancer patients, non-platinum drugs such as doxorubicin, paclitaxel, gemcitabine, docetaxel and etoposide are recommended ( 5 ). (frontiersin.org)
  • Paclitaxel and docetaxel have been shown to not have any added benefit in vitro to SBP-101 alone. (thepilotnews.com)
  • A combined analysis of two trials found that trastuzumab with adjuvant chemotherapy (doxorubicin, cyclophosphamide and paclitaxel) improved the relative risk of disease-free survival by 52% (HR 0.48, 95% CI 0.39 to 0.59), compared with multiple control groups receiving different chemotherapy regimens. (nps.org.au)
  • The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. (stanford.edu)
  • ECOG 2198 examined the cardiac effects of paclitaxel plus trastuzumab (TH) given prior to doxorubicin plus cyclophosphamide (AC) in 234 HER-2-positive (2+ or 3+) stage II breast cancer patients. (cancernetwork.com)
  • 300?nM Cyclophosphamide (Brand Cytoxan, Baxter, Germany) (cells will end up being known as 4xAC) accompanied by 4 cycles of 20?nM Paclitaxel (Brand Taxol, EBEWE Pharma, Austria) (cells will end up being known as 4xAC? (ap26113.com)
  • Completed: 9-ING-41 combined with standard anticancer agents: The 3+3 dose escalation study design will be used for 8 chemotherapy combination regimens (9-ING-41 plus gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, nab-paclitaxel plus gemcitabine, paclitaxel plus carboplatin, pemetrexed plus carboplatin) to identify the MTD/RP2D of each regimen. (outcomes4me.com)
  • Part 3: A randomized Phase 2 study of 9-ING-41 either once or twice weekly with gemcitabine and nab-paclitaxel (GA) versus GA alone for patients with previously untreated metastatic or locally advanced pancreatic cancer is now open. (outcomes4me.com)
  • Treatment with gemcitabine, topotecan, and doxorubicin have been shown to significantly increase the in vitro toxicity of SBP-101 in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. (thepilotnews.com)
  • Utilizing the VDID8 + murine ovarian cancer model (ID8 + C57Bl/6 ovarian cells overexpressing both VEGF and Defensin), the efficacy of SBP-101 in combination with either gemcitabine, topotecan, or doxorubicin was evaluated. (thepilotnews.com)
  • Gemcitabine and topotecan alone had little effect on the overall survival of the mice, whereas either SBP-101 or doxorubicin treatment alone significantly increased median mouse survival time. (thepilotnews.com)
  • But a study by the Eastern Cooperative Oncology Group (ECOG) now suggests the risk is small when trastuzumab is combined with paclitaxel (Taxol), and, for the most part, cardiac changes are reversible. (cancernetwork.com)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • Patients were randomized to paclitaxel 175 mg/m² every 3 weeks for 4 weeks plus trastuzumab for 10 weeks followed by AC (60/600 mg/m²) every 3 weeks for 4 weeks, or to the same treatment with trastuzumab given for 52 weeks. (cancernetwork.com)
  • This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. (ucy.ac.cy)
  • The combinations seem very unusual, particularly combining Abraxane with Faslodex. (breastcancer.org)
  • Inhibition of Growth Cancer chemotherapy has often been seen as a last resort after surgery and irradiation have failed but there has been growing use of adjuvant chemotherapy in combined modality treatments. (present5.com)
  • Ovarian cancer subtypes can now be identified with different clinical and genomic characteristics, which may influence response to treatments beyond the standard carboplatin/paclitaxel regimen. (jnccn.org)
  • Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. (ucy.ac.cy)
  • The results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the platinum-resistant population where few options exist," said Dr. Simpson. (thepilotnews.com)
  • The poster concludes that the treatment of C57Bl/6 mice containing VDID8 + ovarian cancer with SBP-101 in combination with doxorubicin significantly prolonged survival and decreased overall tumor burden. (thepilotnews.com)
  • The TTFields were applied alone and in combination with paclitaxel and doxorubicin. (biomedcentral.com)
  • The results indicate that TTFields alone and in combination with paclitaxel and doxorubicin effectively reduce the viability of both wild type and MDR cell sub-lines and thus can potentially be used as an effective treatment of drug resistant tumors. (biomedcentral.com)
  • The SBP-101 and doxorubicin combination mice had the greatest survival time with a 265% increase in median survival compared to untreated animals. (thepilotnews.com)
  • The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. (tmu.edu.tw)
  • EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs. (tmu.edu.tw)
  • Chemotherapy trials explore combining traditional chemotherapy with immune checkpoint inhibitors like atezolizumab and pembrolizumab. (drtylerbuckley.com)
  • An in vivo study showed that aerosolized administration of an adenovector expressing the GFP-TRAIL fusion protein from the human telomerase reverse transcriptase promoter (designated Ad/gTRAIL) also decreased the number of lung metastases from both doxorubicin-sensitive and doxorubicin-resistant breast cancer cell lines. (elsevierpure.com)
  • Niraparib combined with anlotinib achieved median PFS of 11 months, disease re-progression, and the patient was switched to niraparib combined with letrozole from October 2021. (frontiersin.org)
  • Combining these treatments has improved survival significantly over the years. (cancer.org)
  • Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. (medilib.ir)
  • human breast cancer cells MCF-7 and their mitoxantrone-resistant sub lines MCF-7/Mx and human breast cancer cells MDA-MB-231 and their doxorubicin resistant MDA-MB-231/Dox cells. (biomedcentral.com)
  • Studies have also shown that it can slow down the growth of breast cancer tumors when combined with chemotherapy drugs like doxorubicin or paclitaxel. (fenbenmed.com)
  • Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). (ichgcp.net)
  • The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. (ichgcp.net)
  • This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others. (facingourrisk.org)
  • The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune response, which is intended to target HER-2-expressing tumor cells, and may induce tumor regression or slow progression of disease. (stanford.edu)
  • This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable). (facingourrisk.org)
  • Appropriate antiemetic therapy combined with targeted patient education, clear communication, and management of patient expectations results in optimal emetogenic control. (medscape.com)
  • Assess left ventricular ejection fraction before and regularly during and after treatment with doxorubicin. (medilib.ir)
  • One study compared PLD plus carbo given to women every three weeks versus the standard treatment (paclitaxel (PAC)/carbo every three weeks), and the other added PLD to the standard treatment and compared it with standard treatment only (the latter study also included other treatments not relevant to this review). (cochrane.org)
  • Additionally, combining DFMO with ivospemin in vitro resulted in a cooperative antiproliferative response. (thepilotnews.com)
  • The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. (medilib.ir)
  • Initially in paclitaxel treated patients and, after May 2002, all patients received granulocyte growth factor with each cycle. (nih.gov)